Sensome Raises $9 Million B Round with Equity Investment from Asahi Intecc
Sensome, the company responsible for revolutionizing connected medical devices with the creation of the world's smallest biological tissue sensor, has today announced that they have successfully completed a $9 million dollar financing round, contributed to both by historical investors, such as Kurma Partners, Idinvest Partners, BNP Paribas Développement and Paris-Saclay Seed Fund, and also by Asahi Intecc Co. Ltd from Japan, a world leader in guidewire technology. With this investment, Sensome will test the clinical performance of their first product Clotild®, a proprietary connected guidewire, and get it ready for market. Sensome and Asahi have also agreed to a two-year development plan to design a new connected guidewire for the treatment of ischemic stroke, the leading cause of long-term disability, combining Sensome's proprietary micro-sensor and Asahi's Chikai guidewire.
Ischemic stroke can now be treated by removing the clot blocking the brain blood vessel using mechanical thrombectomy devices. At the current moment, the clot is only successfully removed on the first attempt in one of every three cases, however Sensome's new technology will greatly increase their chance, as it will transform these guidewires with it's tissue sensor.
CEO and co-founder of Sensome, Franz Bozsak, stated that 'the partnership with Ashai will demonstrate how Sensome's sensor technology can be integrated seamlessly into any-high performance medical device.'
To find out more, read the press release by clicking here.